Autolus Therapeutics plc (AUTL)
AUTL Stock Price Chart
Explore Autolus Therapeutics plc interactive price chart. Choose custom timeframes to analyze AUTL price movements and trends.
AUTL Company Profile
Discover essential business fundamentals and corporate details for Autolus Therapeutics plc (AUTL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Jun 2018
Employees
647.00
Website
https://www.autolus.comCEO
Christian Martin Itin
Description
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
AUTL Financial Timeline
Browse a chronological timeline of Autolus Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.22, while revenue estimate is $29.74m.
Earnings released on 14 May 2026
EPS came in at -$0.27 surpassing the estimated -$0.29 by +6.90%, while revenue for the quarter reached $26.22m , missing expectations by -0.18%.
Earnings released on 27 Mar 2026
EPS came in at -$0.34 falling short of the estimated -$0.26 by -30.80%, while revenue for the quarter reached $24.29m , beating expectations by +1.56%.
Earnings released on 12 Nov 2025
EPS came in at -$0.30 falling short of the estimated -$0.23 by -30.43%, while revenue for the quarter reached $21.19m , missing expectations by -13.16%.
Earnings released on 12 Aug 2025
EPS came in at -$0.18 surpassing the estimated -$0.24 by +25.00%, while revenue for the quarter reached $20.92m , missing expectations by -0.74%.
Earnings released on 8 May 2025
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%, while revenue for the quarter reached $8.98m , beating expectations by +309.13%.
Earnings released on 20 Mar 2025
EPS came in at -$0.09 surpassing the estimated -$0.21 by +57.14%, while revenue for the quarter reached $29.00k , missing expectations by -98.09%.
Earnings released on 12 Nov 2024
EPS came in at -$0.31 falling short of the estimated -$0.21 by -47.62%.
Earnings released on 8 Aug 2024
EPS came in at -$0.22 falling short of the estimated -$0.19 by -15.79%.
Earnings released on 17 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.10 by -140.00%, while revenue for the quarter reached $10.09m , beating expectations by +0.91%.
Earnings released on 14 Mar 2024
EPS came in at -$0.44 falling short of the estimated -$0.26 by -69.23%, while revenue for the quarter reached $1.78m , beating expectations by +393.06%.
Earnings released on 2 Nov 2023
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%, while revenue for the quarter reached $406.00k , beating expectations by +35.33%.
Earnings released on 3 Aug 2023
EPS came in at -$0.26 falling short of the estimated -$0.22 by -18.18%.
Earnings released on 4 May 2023
EPS came in at -$0.23 surpassing the estimated -$0.28 by +17.86%, while revenue for the quarter reached $1.29m , beating expectations by +822.86%.
Earnings released on 7 Mar 2023
EPS came in at -$0.23 surpassing the estimated -$0.31 by +25.81%, while revenue for the quarter reached $3.83m , beating expectations by +992.86%.
Earnings released on 3 Nov 2022
EPS came in at -$0.47 falling short of the estimated -$0.46 by -2.17%, while revenue for the quarter reached $2.37m , beating expectations by +1.54k%.
Earnings released on 4 Aug 2022
EPS came in at -$0.46 falling short of the estimated -$0.42 by -9.52%.
Earnings released on 5 May 2022
EPS came in at -$0.41 surpassing the estimated -$0.51 by +19.61%, while revenue for the quarter reached $166.00k , missing expectations by -3.17%.
Earnings released on 10 Mar 2022
EPS came in at -$0.51 falling short of the estimated -$0.49 by -4.08%, while revenue for the quarter reached $823.00k , missing expectations by -3.72%.
Earnings released on 3 Nov 2021
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%, while revenue for the quarter reached $236.00k , missing expectations by -5.60%.
Earnings released on 5 Aug 2021
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%, while revenue for the quarter reached $1.51m , missing expectations by -8.39%.
AUTL Stock Performance
Access detailed AUTL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
